Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoradiation following induction chemotherapy in locally advanced, unresectable pancreatic cancer
2009-014476-21Phase 3Completed
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Dec 2012
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemcitabine, oxaliplatin, folinic acid, irinotecan and fluorouracil in pancreatic cancer (PC) (2 arms), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Primary endpoint: Overall survival. Started Dec 2012; status: completed.
02
Drugs
gemcitabineoxaliplatinfolinic acidirinotecanfluorouracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2009-014476-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014476-21.